There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Shares of Novavax Inc. (NVAX) traded 20% higher on Wednesday morning after the company expressed optimism about receiving traditional approval from the U.S. Food and Drug Administration (FDA) for its ...

Novavax's COVID vaccine was approved under an emergency use authorization in August 2022, and the company has pursued full ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve ...

At FDA, full vaccine approval is the gold standard. The agency was on track to sign off on Novavax’s license by its April 1 target date, according to two people with direct knowledge of the situation ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...